680231-55-4

Upstream product

• 680231-48-5 (2R,3S)-3-azido-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one 
• 680231-49-6 (2R,3S)-3-amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one 
• 680231-47-4 (2R,3R)-3-hydroxy-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one 
• 680231-54-3 ((6R,7S)-8-oxo-6-phenyl-6,7,8,9-tetrahydro-5-oxa-9-aza-benzocycIohepten-7-yl)-carbamic acid tert-butyl ester 
• 106-96-7 propargyl bromide 

Downstream Products

• 680228-55-1 N₂-[(3,5-difluorophenyl)acetyl]-N₁-[(2R,3S)-4-oxo-2-phenyl-5-prop-2-yn-1-yl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide 
• 680231-56-5 (2R,3S)-3-amino-2-phenyl-5-prop-2-yn-1-yl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one 

Relevant academic research and scientific papers

CHEMICAL COMPOUNDS

The invention provides a new method for treating disorders associated with activation of the Notch signal transduction pathway comprising administering an effective amount of a compound of Formula (I), in free form or in a pharmaceutically acceptable salt

NOVEL LACTAMS AND USES THEREOF

Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ? protein production and neurological disorders such as Alzheimer's disease.. These compounds inhibit γ secretase and thereby inhibit the production of amyloid ? protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.